AstraZeneca: PharmaVitae Profile

Introduction

This analysis examines the historical and forecast performance for AstraZeneca in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Features and benefits

* Gain insight into AstraZeneca's strategic outlook across the next 6 years
* Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source

Highlights

Strategic insight into the prospects for AstraZeneca over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.

Your key questions answered

* Benchmark AstraZeneca's performance against key rivals in the prescription pharmaceutical sector
* Assess the importance of Crestor, set to become the industry's biggest-selling product, to AstraZeneca's forecast growth performance
* Analyse AstraZeneca's high level of anticipated exposure to flagship product patent expiries through to 2015 and the impact on company strategy

[Studien Infos ausblenden]

Executive Summary
Key findings
AstraZeneca prescription pharma sales outlook
AstraZeneca financial outlook
Key developments
[Missing title]
AstraZeneca discontinues development of mixed dyslipidemia candidate
AstraZeneca discontinues development of respiratory syncytial virus candidate
AstraZeneca receives CRL from FDA for oral antiplatelet product Brilinta…
…but secures European approval
Upcoming developments
SWOT analysis
Weaknesses
Opportunities
Threats
ABOUT THIS PROFILE
PharmaVitae Explorer database
Chapter structure
Strategic Insight
Company Introduction
Company Sales
Company Financials
Key Products
Data sourcing
Analyst consensus
STRATEGIC INSIGHT
Key findings
Strategic insight
Precariously high exposure to generic competition
Failure to deliver new products to commercial arena has accelerated portfolio maturity
Operating performance and cash generative capabilities remain strong
Emerging markets growth will partially offset generic exposure in US/EU
Summary
COMPANY INTRODUCTION
Key findings
Background
Key corporate developments
M&A history
Subsequent M&A activity
M&A strategy
SALES ANALYSIS
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2004–16
Product analysis
Product analysis, 2004–10
Product analysis, 2010–16
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Launch analysis, 2010–16
Core analysis, 2010–16
Expiry analysis, 2010–16
Launch/core/expiry configuration, 2010–16
Molecule type analysis
Externalization analysis
FINANCIAL ANALYSIS
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2004-10
Operating costs and profit analysis
Operating costs and profit analysis, 2004–10
Operating cost ratio and profit margin analysis, 2004–10
Operating cost ratio and profit margin analysis, 2010–16
Operating costs and profit analysis, 2010–16
PRODUCT ANALYSIS
Overview
Crestor
Symbicort
Nexium
Brilinta
Seroquel
Fostamatinib
Dapagliflozin
TC-5214
AstraZeneca pipeline overview
APPENDIX
Abbreviations
Exchange rates

[Inhaltsverzeichnis ausblenden]